Cancer Family
Intestinal Neoplasm
CI-CAN-00000209Explore in graph →
Non-malignant1,892 active trials21 approved drugs383 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000209Explore in graph →
Clinical trials
9,155 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06992258 | A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer(FRUITION) | recruiting | Phase 2 | 120 | Criterium, Inc.INDUSTRY | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07795749 | Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B) | recruiting | Phase 2 | 55 | University of California, IrvineOTHER | 1 | Aug 31, 2026 |
| clinicaltrials |
| NCT04486378 | A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer | active not recruiting | Phase 2 | 327 | BioNTech SEINDUSTRY | 7 | Aug 28, 2026 | clinicaltrials |
| NCT07793253 | Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer | not yet recruiting | Phase 2 | 55 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07071961 | Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial] | recruiting | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07224022 | Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer(NACho) | not yet recruiting | Phase 2 | 24 | John Strickler, M.D.OTHER | 0 | Aug 27, 2026 | clinicaltrials |
| NCT07474727 | A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer | recruiting | Phase 2 | 180 | Multitude Therapeutics Inc.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07789210 | A Single-Arm, Phase II, Multicenter Clinical Study of Neoadjuvant Encorafenib Plus Cetuximab N01 and mFOLFOX6 in Patients With Locally Advanced BRAF V600E-Mutant Colorectal Cancer With or Without Resectable Metastases(NEORAF) | recruiting | Phase 2 | 25 | Zhejiang UniversityOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07790510 | HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 180 | Haisco Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07551778 | Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 42 | BOE Technology Group Co., Ltd.INDUSTRY | 0 | Aug 26, 2026 | clinicaltrials |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)(STARTRK-2) | active not recruiting | Phase 2 | 534 | Hoffmann-La RocheINDUSTRY | 16 | Aug 25, 2026 | clinicaltrials |
| NCT04851119 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | recruiting | Phase 1 / Phase 2 | 147 | Children's Oncology GroupNETWORK | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06617858 | Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment | recruiting | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07594626 | BMS-986504 in Combination With Pemetrexed for the Treatment of Metastatic Solid Tumors With MTAP Deletion | recruiting | Phase 1 / Phase 2 | 72 | Northwestern UniversityOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT02008656 | Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management | active not recruiting | Phase 2 | 358 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03190941 | Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients | recruiting | Phase 1 / Phase 2 | 110 | National Cancer Institute (NCI)NIH | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03113500 | Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma | active not recruiting | Phase 2 | 48 | City of Hope Medical CenterOTHER | 2 | Aug 21, 2026 | clinicaltrials |
| NCT03965234 | Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases | recruiting | Phase 1 / Phase 2 | 99 | Roswell Park Cancer InstituteOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05677113 | A Study of QBECO Versus Placebo in the Treatment of Colorectal Cancer That Has Spread to the Liver(PERIOP-06) | active not recruiting | Phase 2 | 115 | Sunnybrook Health Sciences CentreOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04205968 | Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers | recruiting | Phase 2 | 94 | SWOG Cancer Research NetworkNETWORK | 1 | Aug 20, 2026 | clinicaltrials |
| NCT05254327 | Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001 | recruiting | Phase 2 | 118 | University of NebraskaOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07235293 | A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer. | recruiting | Phase 2 | 90 | Kahr Bio Australia Pty LtdINDUSTRY | 2 | Aug 20, 2026 | clinicaltrials |
| NCT07636785 | A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors(SPKTAHC) | recruiting | Phase 1 / Phase 2 | 111 | VM Discovery, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07774754 | Radiotherapy Combined With Capeox Chemotherapy, Sintilimab and Suvemcitug in Locally Advanced pMMR Rectal Cancer:a Prospective Clinical Trial(RADIANT) | not yet recruiting | Phase 2 | 18 | Sun Yat-sen UniversityOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06728072 | Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer | recruiting | Phase 2 | 97 | Virginia Commonwealth UniversityOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06792695 | A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer(CANTOR) | recruiting | Phase 2 | 80 | AstraZenecaINDUSTRY | 12 | Aug 18, 2026 | clinicaltrials |
| NCT07735624 | RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer(RECTIFY-1) | recruiting | Phase 2 | 16 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT02955940 | An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | active not recruiting | Phase 2 | 10 | Incyte CorporationINDUSTRY | 2 | Aug 17, 2026 | clinicaltrials |
| NCT05919264 | FOG-001 in Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 619 | Parabilis Medicines, Inc.INDUSTRY | 2 | Aug 17, 2026 | clinicaltrials |
| NCT07440290 | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT04230759 | Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group(RADIANCE) | active not recruiting | Phase 2 | 180 | Goethe UniversityOTHER | 3 | Aug 14, 2026 | clinicaltrials |
| NCT07425054 | ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer(CHART-AC) | recruiting | Phase 2 | 33 | Jennifer DorthOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07765667 | NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARC(CRI-KEV) | not yet recruiting | Phase 2 | 100 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT05288205 | Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation | recruiting | Phase 1 / Phase 2 | 240 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05722288 | Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers | active not recruiting | Phase 2 | 49 | City of Hope Medical CenterOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06399757 | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 100 | Apollo Therapeutics LtdINDUSTRY | 1 | Aug 13, 2026 | clinicaltrials |
| NCT04007770 | Acupuncture Pilot Study for Cancer-related Cognitive Function | active not recruiting | Phase 2 | 48 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07079462 | Comparing 18F-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal Metastasis | active not recruiting | Phase 2 | 40 | Fudan UniversityOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07136077 | A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy | active not recruiting | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07277322 | Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases | recruiting | Phase 1 / Phase 2 | 24 | Dan FengOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04068610 | COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC | active not recruiting | Phase 1 / Phase 2 | 61 | MedImmune LLCINDUSTRY | 5 | Aug 11, 2026 | clinicaltrials |
| NCT05592626 | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors(START-001) | recruiting | Phase 1 / Phase 2 | 366 | Marengo Therapeutics, Inc.INDUSTRY | 4 | Aug 11, 2026 | clinicaltrials |
| NCT05706129 | A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 270 | Lumara Bio Oncologics GmbHINDUSTRY | 2 | Aug 11, 2026 | clinicaltrials |
| NCT07071714 | A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer | active not recruiting | Phase 2 | 103 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06577194 | Neoadjuvant Short-Course Radiotherapy Followed by CAPOX Plus PD-1 Antibody and IL-2 in Locally Advanced Rectal Cancer (PRIDE01) | active not recruiting | Phase 2 | 35 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07550088 | BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases | recruiting | Phase 2 | 17 | Darren Sigal, MDOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07755124 | Dietary Arginine Deprivation Combined With Chemoradiotherapy for Neoadjuvant Treatment of Rectal Cancer: A Randomized Controlled Trial | not yet recruiting | Phase 1 / Phase 2 | 140 | West China HospitalOTHER | 0 | Aug 10, 2026 | clinicaltrials |
| NCT03844620 | Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer | active not recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT06751329 | A Study of DM002 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 280 | Xadcera Biopharmaceutical (Suzhou) Co., Ltd.INDUSTRY | 2 | Aug 7, 2026 | clinicaltrials |
| NCT07162714 | SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer(STAR) | recruiting | Phase 2 | 30 | Zhejiang Cancer HospitalOTHER | 1 | Aug 7, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Sep 1, 2026source: clinicaltrials